

Marcus Schmidt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7834384/publications.pdf>

Version: 2024-02-01

211
papers

10,966
citations

66250

44
h-index

38517

99
g-index

239
all docs

239
docs citations

239
times ranked

14536
citing authors

#	ARTICLE	IF	CITATIONS
1	The preoperative G8 geriatric screening tool independently predicts survival in older patients with endometrial cancer: results of a retrospective single-institution cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 851-863.	1.2	4
2	Frailty assessment tools predict perioperative outcome in elderly patients with endometrial cancer better than age or BMI alone: a retrospective observational cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1551-1560.	1.2	9
3	Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa). <i>Breast Cancer Research and Treatment</i> , 2022, 191, 147-157.	1.1	6
4	Metronomic Chemotherapy for Metastatic Breast Cancer. <i>Oncology Research and Treatment</i> , 2022, 45, 12-17.	0.8	10
5	Efficacy and Safety of Immunotherapy for Cervical Cancer—A Systematic Review of Clinical Trials. <i>Cancers</i> , 2022, 14, 441.	1.7	12
6	G-8 Geriatric Screening Tool Independently Predicts Progression-Free Survival in Older Ovarian Cancer Patients Irrespective of Maximal Surgical Effort: Results of a Retrospective Cohort Study. <i>Gerontology</i> , 2022, 68, 1101-1110.	1.4	11
7	New Opportunities in Advanced Breast Cancer. <i>Oncology Research and Treatment</i> , 2022, 45, 1-3.	0.8	1
8	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 403-420.	0.8	43
9	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. <i>Breast Care</i> , 2022, 17, 421-429.	0.8	9
10	A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany. <i>Breast</i> , 2022, 65, 1-7.	0.9	5
11	Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. <i>European Journal of Cancer</i> , 2022, 173, 10-19.	1.3	42
12	Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 61-72.	1.7	3
13	Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1833-1842.	1.2	18
14	Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS) Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50 21		
15	Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2117-2126.	1.2	4
16	Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2148-2158.	3.2	12
17	Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores. <i>Cancers</i> , 2021, 13, 844.	1.7	7
18	The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells. <i>Anticancer Research</i> , 2021, 41, 1243-1250.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2 ⁻ breast cancer resistant to endocrine therapy: VinoMetro [®] AGO-B-046. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3391-3400.	1.2	6
20	Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men. <i>JAMA Oncology</i> , 2021, 7, 565.	3.4	24
21	Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2 ⁻ Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2 ⁻ Breast Cancer. <i>Cancers</i> , 2021, 13, 1810.	1.7	13
22	Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment [®] driven analyses from the ExteNET study. <i>European Journal of Cancer</i> , 2021, 150, 268-277.	1.3	3
23	Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 3626.	1.7	9
24	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 1151-1161.	5.1	248
25	Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1291.	3.4	24
26	Immunomodulating Therapies in Breast Cancer [®] From Prognosis to Clinical Practice. <i>Cancers</i> , 2021, 13, 4883.	1.7	15
27	Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). <i>European Journal of Cancer</i> , 2021, 156, 138-148.	1.3	4
28	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 228-235.	0.8	20
29	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. <i>Breast Care</i> , 2021, 16, 214-227.	0.8	51
30	Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy. <i>Breast Care</i> , 2021, 16, 1-7.	0.8	4
31	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1112-1120.	0.8	17
32	AGO Algorithms for the Treatment of Breast Cancer: Update 2021. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 1101-1111.	0.8	6
33	Role of integrins in the metastatic spread of high-grade serous ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	0.8	3
34	Prognostic and predictive markers for adjuvant therapy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 100-105.	0.9	0
35	Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. <i>Cancers</i> , 2020, 12, 2787.	1.7	12
36	Prognostic Significance of Interferon- β and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7178.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2 ⁺ advanced breast cancer (PALOMA-1, TRIO-18). <i>Breast Cancer Research and Treatment</i> , 2020, 183, 419-428.	1.1	73
38	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. <i>Breast Care</i> , 2020, 15, 294-309.	0.8	47
39	GAIN-2: Neo-/adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 516-516.	0.8	2
40	Abstract P6-12-06: Shared decision making (SDM) in routine care treatment of breast cancer patients - A survey of patients following surgery. , 2020, , .		0
41	Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. <i>Cancer Research</i> , 2020, 80, CT301-CT301.	0.4	31
42	Abstract OT3-14-02: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy - Precycle. , 2020, , .		0
43	Abstract P3-07-08: Comparison of MammaTyper [®] RT-qPCR based subtyping with simulated breast cancer prognostic signatures. , 2020, , .		0
44	Abstract P5-11-15: Estetrol for treatment of advanced ER+/HER2- breast cancer. , 2020, , .		2
45	Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1100-1109.	0.8	1
46	The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1113-1120.	0.8	20
47	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 247-255.	0.8	32
48	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 224-245.	0.8	72
49	LIP ⁺ promoted lipid storage mediates adaptation to oxidative stress in breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 901-915.	2.3	41
50	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). <i>Anti-Cancer Drugs</i> , 2019, 30, 394-401.	0.7	3
51	Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. <i>International Journal of Medical Sciences</i> , 2019, 16, 1188-1198.	1.1	19
52	Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1328-1335.	0.8	3
53	Atezolizumab for the treatment of triple-negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1-5.	1.9	78
54	Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid. <i>Cancer Immunology Research</i> , 2019, 7, 113-122.	1.6	29

#	ARTICLE	IF	CITATIONS
55	A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients. Archives of Gynecology and Obstetrics, 2019, 299, 239-246.	0.8	4
56	Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). , 2019, , .		2
57	Investigation of the efficacy of imidazolyl ethanamide pentandioic acid (IEPA) to reduce chemotherapy-induced myelosuppression (CIM) in breast cancer patients.. Journal of Clinical Oncology, 2019, 37, e23098-e23098.	0.8	1
58	Low-dose metronomic chemotherapy (LDMC) as an efficient treatment option in metastatic breast cancer: Results of an exploratory case-control study.. Journal of Clinical Oncology, 2019, 37, e12578-e12578.	0.8	0
59	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Research, 2018, 20, 15.	2.2	71
60	Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. Journal of Geriatric Oncology, 2018, 9, 163-169.	0.5	10
61	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) â€œ Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde. 2018. 78. 1056-1088.	0.8	69
62	Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery. Breast Care, 2018, 13, 324-330.	0.8	22
63	What Is the Best Management of cN0pN1 (sn) Breast Cancer Patients. Breast Care, 2018, 13, 331-336.	0.8	13
64	Cardiac late events in German breast cancer patients: a validation study on the agreement between patient self-reports and information from physicians. BMC Cardiovascular Disorders, 2018, 18, 218.	0.7	8
65	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) â€œ Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Und Frauenheilkunde. 2018. 78. 927-948.	0.8	59
66	Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Diagnostic Pathology, 2018, 13, 83.	0.9	2
67	Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients. Breast Care, 2018, 13, 272-276.	0.8	16
68	Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879332.	1.4	104
69	Palbociclibâ€”The First of a New Class of Cell Cycle Inhibitors. Recent Results in Cancer Research, 2018, 211, 153-175.	1.8	9
70	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care, 2018, 13, 209-215.	0.8	20
71	Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. European Journal of Cancer, 2018, 102, 1-9.	1.3	68
72	Prevalence of Cardiac Disease in Breast Cancer Patients at Time of Diagnosis Compared to the General Female Population in Germany. Breast Care, 2018, 13, 264-271.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 1247-1258.	5.1	79
74	Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.. <i>Journal of Clinical Oncology</i> , 2018, 36, 568-568.	0.8	3
75	Induced Myelosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups. <i>Blood</i> , 2018, 132, 5106-5106.	0.6	1
76	Self-reported long-term cardiac morbidity in breast cancer patients: a retrospective cohort study in Germany (PASSOS Heart Study). <i>Breast Cancer Research and Treatment</i> , 2017, 163, 595-604.	1.1	14
77	Primary metastatic breast cancer in the era of targeted therapy – Prognostic impact and the role of breast tumour surgery. <i>European Journal of Cancer</i> , 2017, 83, 116-124.	1.3	25
78	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017. <i>Breast Care</i> , 2017, 12, 184-191.	0.8	11
79	Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review. <i>Breast Care</i> , 2017, 12, 168-171.	0.8	16
80	News from ASCO 2017. <i>Breast Care</i> , 2017, 12, 266-268.	0.8	0
81	Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1079-1087.	0.8	4
82	A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 63-72.	1.1	35
83	3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). <i>Breast Cancer Research and Treatment</i> , 2017, 161, 143-152.	1.1	19
84	Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 329-333.	0.8	12
85	A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro. <i>Breast</i> , 2017, 36, S51.	0.9	0
86	Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. <i>Oncotarget</i> , 2017, 8, 72281-72301.	0.8	11
87	Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1001-1001.	0.8	55
88	Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1061-1061.	0.8	25
89	A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1115-TPS1115.	0.8	0
90	Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12547-e12547.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis. <i>Oncology Research and Treatment</i> , 2016, 39, 102-110.	0.8	18
92	Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index. <i>Breast Care</i> , 2016, 11, 22-26.	0.8	9
93	c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients. <i>Oncology Letters</i> , 2016, 12, 2001-2007.	0.8	8
94	Palbociclib - from Bench to Bedside and Beyond. <i>Breast Care</i> , 2016, 11, 177-181.	0.8	10
95	Feasibility of induced metabolic bioluminescence imaging in advanced ovarian cancer patients: first results of a pilot study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1909-1916.	1.2	5
96	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. <i>Breast Cancer Research</i> , 2016, 18, 67.	2.2	140
97	Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 599-606.	0.8	11
98	Fulvestrant for the treatment of endometrial cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 475-483.	1.9	6
99	Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 3837-3847.	1.6	28
100	Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients with brain metastases from breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2070-2070.	0.8	2
101	Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO-AGO intergroup Trial-TRIAS.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5522-5522.	0.8	3
102	Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy. <i>PLoS ONE</i> , 2016, 11, e0167585.	1.1	44
103	Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. <i>Oncotarget</i> , 2016, 7, 74846-74859.	0.8	16
104	Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS) HerSCin.. <i>Journal of Clinical Oncology</i> , 2016, 34, 581-581.	0.8	7
105	Feasibility of an induced metabolic bioluminescence imaging technique in ovarian cancer: Results of a pilot study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17093-e17093.	0.8	0
106	Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial. <i>Cancer Research</i> , 2016, 76, CT020-CT020.	0.4	2
107	First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. <i>Anticancer Research</i> , 2016, 36, 967-74.	0.5	10
108	<sc>JNK</sc>-dependent gene regulatory circuitry governs mesenchymal fate. <i>EMBO Journal</i> , 2015, 34, 2162-2181.	3.5	31

#	ARTICLE	IF	CITATIONS
109	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 983-991.	0.8	863
110	Identification of sample annotation errors in gene expression datasets. <i>Archives of Toxicology</i> , 2015, 89, 2265-2272.	1.9	46
111	Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. <i>Breast Care</i> , 2015, 10, 168-172.	0.8	19
112	The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 686-697.	2.3	30
113	Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 555-562.	1.2	5
114	Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 1355-1360.	0.8	7
115	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 25-35.	5.1	1,574
116	The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5557-5557.	0.8	1
117	Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).. <i>Journal of Clinical Oncology</i> , 2015, 33, 570-570.	0.8	5
118	The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 572-572.	0.8	1
119	Abstract P2-05-04: Gene expression associated with poor prognosis of young TNBC patients. , 2015, , .		0
120	Abstract P6-08-20: Prognostic significance of the interferon metagene in node-negative breast cancer depends on the molecular subtype. , 2015, , .		0
121	Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project. , 2015, , .		1
122	Abstract 5485: Coactivator PPAR γ 1B Ala203Pro polymorphism is linked with estrogen-related receptor function and breast cancer outcome. , 2015, , .		1
123	Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 5277-85.	0.5	29
124	Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 2205.	1.0	23
125	Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: Results of the AGO pattern of care studies from the years 2013, 2009, and 2006. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 2087-2093.	1.2	3
126	Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients. <i>BMC Cancer</i> , 2014, 14, 952.	1.1	34

#	ARTICLE	IF	CITATIONS
127	Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer—a problem still to be solved. <i>Annals of Oncology</i> , 2014, 25, 754.	0.6	7
128	Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice. <i>MABs</i> , 2014, 6, 968-977.	2.6	26
129	Chemotherapy in Early Breast Cancer: When, How and Which One?. <i>Breast Care</i> , 2014, 9, 154-160.	0.8	18
130	Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer. <i>Genomics Data</i> , 2014, 2, 354-356.	1.3	9
131	GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva. <i>BMC Cancer</i> , 2014, 14, 760.	1.1	19
132	Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 54-60.	1.2	52
133	Loss of circadian clock gene expression is associated with tumor progression in breast cancer. <i>Cell Cycle</i> , 2014, 13, 3282-3291.	1.3	193
134	Prognostic relevance of glycosylation-associated genes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 295-305.	1.1	77
135	Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1097-1102.	1.2	20
136	Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: Results of an explorative, retrospective study. <i>Oncology Reports</i> , 2014, 31, 2213-2219.	1.2	16
137	Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). , 2014, , .		35
138	German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1009-1009.	0.8	4
139	Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial).. <i>Journal of Clinical Oncology</i> , 2014, 32, 1044-1044.	0.8	2
140	Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e111306.	1.1	40
141	The role of surgery in patients with primary metastatic breast cancer (PMBC) receiving monoclonal antibody treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1097-1097.	0.8	0
142	Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12007-e12007.	0.8	0
143	Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1072-1072.	0.8	2
144	Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 620-620.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 747-754.	1.2	23
146	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 2047-2056.	1.2	28
147	NCOA3 is a selective co-activator of estrogen receptor α -mediated transactivation of PLAC1 in MCF-7 breast cancer cells. <i>BMC Cancer</i> , 2013, 13, 570.	1.1	21
148	Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas. <i>Modern Pathology</i> , 2013, 26, 336-342.	2.9	18
149	German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3531-3539.	0.8	82
150	From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis. <i>Microarrays (Basel, Switzerland)</i> , 2013, 2, 243-264.	1.4	5
151	IGKC and Prognosis in Breast Cancer—Letter. <i>Clinical Cancer Research</i> , 2013, 19, 304-304.	3.2	7
152	Nationwide Analysis on Surgical Staging Procedures and Systemic Treatment for Patients With Endometrial Cancer in Germany. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 105-112.	1.2	15
153	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R86.	2.2	44
154	The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. <i>PLoS ONE</i> , 2013, 8, e68252.	1.1	66
155	Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 602-602.	0.8	1
156	Prognostic significance of the chemokine CXCL13 in node-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 615-615.	0.8	0
157	Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors. <i>Oncolmmunology</i> , 2012, 1, 1156-1158.	2.1	28
158	A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2695-2703.	3.2	237
159	Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach. <i>Oncology Reports</i> , 2012, 28, 429-438.	1.2	83
160	Weeklynab-Paclitaxel in Metastatic Breast Cancer — Summary and Results of an Expert Panel Discussion. <i>Breast Care</i> , 2012, 7, 137-143.	0.8	6
161	Cerebral Metastases of an Endometrial Stromal Sarcoma: Report of the First Case. <i>Onkologie</i> , 2012, 35, 272-274.	1.1	3
162	Tumor architecture exerts no bias on nuclear grading in breast cancer diagnosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 399-403.	1.4	3

#	ARTICLE	IF	CITATIONS
163	A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1149-1159.	1.1	72
164	Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. <i>European Journal of Cancer</i> , 2012, 48, 12-23.	1.3	43
165	Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. <i>BMC Cancer</i> , 2012, 12, 456.	1.1	66
166	Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. <i>BMC Cancer</i> , 2012, 12, 562.	1.1	62
167	Efficacy of psychodynamic short-term psychotherapy for depressed breast cancer patients: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2012, 12, 578.	1.1	13
168	Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e44741.	1.1	33
169	Decentral gene expression analysis for ER+/Her2 ⁺ breast cancer: results of a proficiency testing program for the EndoPredict assay. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 251-259.	1.4	88
170	Absence of ectopic epithelial inclusions in 3,904 axillary lymph nodes examined in sentinel technique. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 621-624.	1.1	22
171	Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1077-1077.	0.8	1
172	Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.. <i>Journal of Clinical Oncology</i> , 2012, 30, 542-542.	0.8	1
173	Prediction of late metastasis in node-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10551-10551.	0.8	1
174	Trastuzumab treatment in patients with advanced breast cancer (ABC) confined to locoregional and skeletal sites: Results from a large noninterventional study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 640-640.	0.8	0
175	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. <i>Clinical Cancer Research</i> , 2011, 17, 6012-6020.	3.2	597
176	Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2011, 47, 2273-2281.	1.3	164
177	A clinically relevant gene signature in triple negative and basal-like breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R97.	2.2	286
178	Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures. <i>PLoS ONE</i> , 2011, 6, e28403.	1.1	93
179	Serum proteome profiling of primary breast cancer indicates a specific biomarker profile. <i>Oncology Reports</i> , 2011, 26, 1051-6.	1.2	22
180	Survival models with preclustered gene groups as covariates. <i>BMC Bioinformatics</i> , 2011, 12, 478.	1.2	17

#	ARTICLE	IF	CITATIONS
181	Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 Å— FEC versus 3 Å— FEC/3 Å— Docetaxel. BMC Cancer, 2011, 11, 140.	1.1	40
182	The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer, 2011, 11, 453.	1.1	36
183	Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Research and Treatment, 2011, 125, 637-646.	1.1	30
184	Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Research and Treatment, 2011, 130, 409-420.	1.1	29
185	Antibody microarray analysis of the serum proteome in primary breast cancer patients. Cancer Biology and Therapy, 2011, 12, 772-779.	1.5	8
186	Systems Biology, Bioinformatics and Medicine Approaches to Cancer Progression Outcomes. , 2011, , 297-307.		0
187	Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Research and Treatment, 2010, 120, 567-579.	1.1	53
188	Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. BMC Bioinformatics, 2010, 11, 276.	1.2	48
189	A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer, 2010, 10, 2.	1.1	32
190	Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. BMC Cancer, 2010, 10, 430.	1.1	1
191	Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer, 2010, 10, 604.	1.1	144
192	ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer. Clinical Cancer Research, 2010, 16, 451-460.	3.2	46
193	ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction. Clinical Cancer Research, 2010, 16, 2391-2401.	3.2	113
194	New Developments in Breast Cancer Therapy Presented at ASCO 2010. Breast Care, 2010, 5, 266-271.	0.8	0
195	Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Research, 2010, 12, R44.	2.2	180
196	Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2â€“Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. Journal of Clinical Oncology, 2009, 27, 1999-2006.	0.8	685
197	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA - Journal of the American Medical Association, 2009, 302, 1429.	3.8	468
198	Coordinates in the Universe of Node-Negative Breast Cancer Revisited. Cancer Research, 2009, 69, 2695-2698.	0.4	39

#	ARTICLE	IF	CITATIONS
199	Surface-enhanced Laser Desorption/Ionisation Time-of-flight Mass Spectrometry to Detect Breast Cancer Markers in Tears and Serum. <i>Cancer Genomics and Proteomics</i> , 2009, 6, 75-83.	1.0	15
200	Cancer and fertility preservation: fertility preservation in breast cancer patients. <i>Breast Cancer Research</i> , 2008, 10, 206.	2.2	50
201	Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5849-5855.	3.2	69
202	Node-Negative Breast Cancer: Which Patients Should Be Treated?. <i>Breast Care</i> , 2008, 3, 237-243.	0.8	5
203	The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer. <i>Cancer Research</i> , 2008, 68, 5405-5413.	0.4	730
204	Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 1512-1519.	2.3	35
205	Sa.33. Interleukin-7 Receptor (IL-7r) Mediated Signaling Effects in Immune Cells:Novel Readout for "Immune Competence". <i>Clinical Immunology</i> , 2006, 119, S116-S117.	1.4	0
206	Reduced Expression of the IL-7 Receptor (CD127) on CD8AA+ T-cells and IL-7 Signalling Defects in Patients With Breast Cancer. <i>Journal of Immunotherapy</i> , 2005, 28, 626-627.	1.2	1
207	Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. <i>Breast Cancer Research</i> , 2005, 7, R256-66.	2.2	31
208	The impact of treatment for genital cancer on quality of life and body image"results of a prospective longitudinal 10-year study. <i>Gynecologic Oncology</i> , 2004, 94, 398-403.	0.6	168
209	Preoperative Assessment of Breast Cancer: Sonography Versus MR Imaging. <i>American Journal of Roentgenology</i> , 2002, 179, 1493-1501.	1.0	148
210	Carcinoma of the Neovagina: Case Report and Review of the Literature. <i>Gynecologic Oncology</i> , 2002, 84, 171-175.	0.6	51
211	Immuno-oncology in triple-negative breast cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 0, 2021, .	0.5	3